Exelixis, Inc. (EXEL) Stock Score, Valuation & Financial Research
Exelixis, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 64/100.
Quick answer for EXEL
Exelixis, Inc. currently has a Wall Street Score of 64/100. The stored market price is $56.12. Its financial score is 44/100. Its valuation score is 93/100. These figures are a research snapshot, not a buy or sell recommendation.
What Exelixis, Inc. does
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatmen
EXEL financial snapshot
- Wall Street Score:
- 64/100
- Current price:
- $56.12
- Market capitalization:
- $14.11B
- Revenue:
- $2.44B
- Net income:
- $860.6M
- Free cash flow:
- $844.3M
- Cash:
- $281.4M
- Total debt:
- $165.9M
- EPS:
- 3.29
- P/E ratio:
- 17.1x
- Financial score:
- 44/100
- Valuation score:
- 93/100
- Revenue score:
- 37/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $844.3M, showing positive cash generation.
- The balance sheet shows $281.4M of cash versus $165.9M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 93/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 44/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research EXEL
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.